EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma

Real-world data from the Danish ABCD study are presented by Astrid Hundebøll Torpe, MD, PhD Fellow, Department of Hematology, Copenhagen University Hospital, Denmark, at the EHA 2026 Congress. She discusses the clinical activity of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma and true extramedullary disease, as well as the ongoing unmet need in this high-risk population.